VEC.L Share News (VEC)

Vectura sales trigger $5m milestone receipt

(ShareCast News) - Vectura said on Wednesday that a sales milestone receipt of $5m has been triggered following confirmation by Novartis that EU/Rest of World combined net sales of its Seebri Breezhaler and Ultibro Breezhaler for the year to the end of December have reached $512m. The milestone will

Vectura gets FDA investigational approval for VR647

(ShareCast News) - Device and formulation business for inhaled airways disease, Vectura Group, announced on Tuesday it has received an 'Investigational New Drug' approval from the US Food and Drug Administration for its VR647 product. The FTSE 250 firm said the approval will allow it to conduct a Ph

Vectura Gets US Approval For Phase I Trial Of Asthma Treatment

Vectura makes 'significant progess' in third quarter

(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced an unaudited pre-close update on Wednesday, ahead of its results for the nine months to 31 December, due in March. The FTSE 250 company said that following the step-change in financial performance anno

Respiratory Medicine-Maker Vectura Breathing Easy Over Revenue Targets

WINNERS & LOSERS SUMMARY: PayPoint Sale And Special Payout Lift Shares

Vectura Group signs development agreement with Mundipharma

(ShareCast News) - Inhaled airways disease device and formulation business Vectura Group announced on Friday that it has signed a development and licence agreement with Mundipharma International Corporation and a US independent associated company as the global development and commercialisation partn

Vectura says Bayer completes EU approval procedure for alternative nebulised delivery

(ShareCast News) - Vectura said on Thursday that its partner Bayer has confirmed completion of the EU regulatory procedure that allows an alternative nebulised delivery for its currently-marketed product Ventavis using the London-listed company's smart nebuliser Fox device. Ventavis has been develop

Vectura says Novartis signs US licensing agreement for COPD treatments

(ShareCast News) - Vectura announced that Swiss pharmaceutical company Novartis has signed a licensing agreement with Sunovion Pharmaceuticals for the US commercialisation rights to three treatments for chronic obstructive pulmonary disease for which it receives royalty revenues. Novartis, whose pro

Vectura confirms positive study results for Ultibro Breezhaler

(ShareCast News) - Inhaled airways disease-focused business Vectura Group confirmed an announcement by its partner Novartis on Thursday. The FTSE 250 firm said the announcement was of positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequ

Vectura earnings surge as Skyepharma merger creates step-change

(ShareCast News) - Inhaler maker Vectura's interim revenue have soared following the merger with rival Skyepharma and a launch of new products. For the six months ended 30 September, revenue increased 183% to £73.9m, compared to the same period last year, primarily due to the completion of the £441m

TOP NEWS: Hikma Signs Development And Licensing Deal With Vectura

Sunday newspaper round-up: OBR, Saudi Aramco, Tesco, BAT, bonds vigilantes

(ShareCast News) - The Office for Budget Responsibility is likely to cut its forecast for UK growth next year by the biggest margin since the peak of the eurozone debt crisis. Philip Hammond's Autumn Statement this week will see the Chancellor set out his multi-billion pound infrastructure plans and

LONDON MARKET CLOSE: Strong US Data, Yellen Comments Point To Fed Hike

Vectura climbs on positive read-across from Novartis, Singer upgrade

(ShareCast News) - Shares in medical device group Vectura were given a boost by expectations of foreign currency gains and investors reading across results from Novartis, with which the London-listed company is partnered on a handful of products. A third-quarter update from Novartis on Tuesday in